United Therapeutics Corporation UTH.F Stock
United Therapeutics Corporation Price Chart
United Therapeutics Corporation UTH.F Financial and Trading Overview
United Therapeutics Corporation stock price | 224 EUR |
Previous Close | 207.4 EUR |
Open | 208 EUR |
Bid | 209.2 EUR x 30000 |
Ask | 210.8 EUR x 30000 |
Day's Range | 208 - 208 EUR |
52 Week Range | 189.8 - 271.4 EUR |
Volume | 10 EUR |
Avg. Volume | 2 EUR |
Market Cap | 9.75B EUR |
Beta (5Y Monthly) | 0.604577 |
PE Ratio (TTM) | 15.083394 |
EPS (TTM) | 18.46 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 231.89 EUR |
UTH.F Valuation Measures
Enterprise Value | 7.84B EUR |
Trailing P/E | 15.083394 |
Forward P/E | 12.879257 |
PEG Ratio (5 yr expected) | 11.93 |
Price/Sales (ttm) | 4.9188595 |
Price/Book (mrq) | 1.895942 |
Enterprise Value/Revenue | 3.959 |
Enterprise Value/EBITDA | 7.561 |
Trading Information
United Therapeutics Corporation Stock Price History
Beta (5Y Monthly) | 0.604577 |
52-Week Change | 2.22% |
S&P500 52-Week Change | 20.43% |
52 Week High | 271.4 EUR |
52 Week Low | 189.8 EUR |
50-Day Moving Average | 201.46 EUR |
200-Day Moving Average | 226.44 EUR |
UTH.F Share Statistics
Avg. Volume (3 month) | 2 EUR |
Avg. Daily Volume (10-Days) | 1 EUR |
Shares Outstanding | 46.85M |
Float | 43.18M |
Short Ratio | N/A |
% Held by Insiders | 1.75% |
% Held by Institutions | 98.92% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 36.75% |
Operating Margin (ttm) | 49.73% |
Gross Margin | 91.01% |
EBITDA Margin | 52.36% |
Management Effectiveness
Return on Assets (ttm) | 10.52% |
Return on Equity (ttm) | 15.66% |
Income Statement
Revenue (ttm) | 1.98B EUR |
Revenue Per Share (ttm) | 43.28 EUR |
Quarterly Revenue Growth (yoy) | 9.70% |
Gross Profit (ttm) | 1.78B EUR |
EBITDA | 1.04B EUR |
Net Income Avi to Common (ttm) | 728.3M EUR |
Diluted EPS (ttm) | 13.79 |
Quarterly Earnings Growth (yoy) | 0.40% |
Balance Sheet
Total Cash (mrq) | 2.86B EUR |
Total Cash Per Share (mrq) | 61.12 EUR |
Total Debt (mrq) | 800M EUR |
Total Debt/Equity (mrq) | 15.62 EUR |
Current Ratio (mrq) | 9.837 |
Book Value Per Share (mrq) | 109.708 |
Cash Flow Statement
Operating Cash Flow (ttm) | 888.6M EUR |
Levered Free Cash Flow (ttm) | 612.24M EUR |
Profile of United Therapeutics Corporation
Country | Germany |
State | MD |
City | Silver Spring |
Address | 1040 Spring Street |
ZIP | 20910 |
Phone | 301 608 9292 |
Website | https://www.unither.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 985 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Q&A For United Therapeutics Corporation Stock
What is a current UTH.F stock price?
United Therapeutics Corporation UTH.F stock price today per share is 224 EUR.
How to purchase United Therapeutics Corporation stock?
You can buy UTH.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for United Therapeutics Corporation?
The stock symbol or ticker of United Therapeutics Corporation is UTH.F.
Which industry does the United Therapeutics Corporation company belong to?
The United Therapeutics Corporation industry is Biotechnology.
How many shares does United Therapeutics Corporation have in circulation?
The max supply of United Therapeutics Corporation shares is 47.06M.
What is United Therapeutics Corporation Price to Earnings Ratio (PE Ratio)?
United Therapeutics Corporation PE Ratio is 12.13434500 now.
What was United Therapeutics Corporation earnings per share over the trailing 12 months (TTM)?
United Therapeutics Corporation EPS is 18.46 EUR over the trailing 12 months.
Which sector does the United Therapeutics Corporation company belong to?
The United Therapeutics Corporation sector is Healthcare.